

## Anatara partnering update

MELBOURNE, 23<sup>rd</sup> June 2020: Anatara Lifesciences Ltd (ASX:ANR) provides an update on partnering discussions for Detach® and GaRP.

### Highlights

- Anatara does not anticipate reaching a partnering agreement by the end of FY 2020 for an animal health product
- Anatara remains in discussions with third parties to progress development of the company's animal health assets to address barriers to partnering
- Anatara continues to progress the human health portfolio and now plans the commencement of a clinical trial of GaRP in irritable bowel syndrome (IBS) in the 4th quarter of calendar 2020
- Anatara is evaluating partnering opportunities for GaRP with multinational consumer health companies

Detach® is a non-antibiotic product which was approved by the Australian Pesticides and Veterinary Medicines Authority (APVMA) as an aid in the control of diarrhoeal disease in piglets (known as scour).

Anatara updates advice that:

- there remains a need for a safe, effective, non-antibiotic solution to control scour in piglets and that there is a similar need in other livestock species, such as poultry.
- opportunities exist for the product globally but with varying requirements for regulatory approval, including additional formulations and in-country field trials.
- Anatara's Detach® oral drench is suited to pre-weaning piglets however this is not a preferred dosage form in larger, post-weaning piglets with feedback suggesting an additional dosage form is required; hence, new formulations need to be developed to enable alternative administration options for post-weaning piglets.
- due to budgetary constraints, Anatara is exploring, through animal health partner companies, options to develop and commercialise Detach® in multiple species.

Anatara is nearing conclusion of a process of due diligence and negotiation with many of the world's leading animal health companies. Anatara's objective being to partner with a company or companies to register Detach® in key overseas markets, develop new formulations and administration methods for Detach® to expand utility, and to develop Detach® for other livestock species such as poultry.



While partnering discussions continue, Anataara does not expect to successfully reach a partnering agreement by the end of FY 2020. As highlighted, feedback suggests that additional dosage forms for piglets is required and furthermore proof of concept data in encouraging indications for other species is also required.

While focussing financial resources on development of GaRP, Anataara has been evaluating development, in collaboration with third parties, additional dosage forms for piglets and to utilise Anataara's intellectual property in other species including in-feed formulations for piglets, formulations for aquaculture and formulations for poultry. These activities may evolve into opportunities in new areas.

CEO Steve Lydeamore commented, "Anataara is engaged in discussions with third parties to progress development of Anataara's animal health assets to address barriers to partnering. We will continue to provide updates to the market as these activities progress."

### **Anataara's Gastrointestinal ReProgramming (GaRP) OTC medicine**

Anataara's GaRP over-the-counter medicine is being developed to specifically target two human gastrointestinal disorders, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). IBS is the most common GI condition affecting approximately 11% of the global population<sup>1</sup> while IBD affects an estimated five million people globally.<sup>2</sup>

GaRP is a single product with multiple benefits, aimed at effectively managing many of the major symptoms experienced by IBS and IBD patients. GaRP has been designed as an everyday option for IBS patients to 1) manage ongoing chronic symptoms and 2) minimise episodic flare ups. The product works in four ways to obtain relief for patients, targeting ingredients to where they are most needed:

1. Reduces pain of episodic flare ups by relaxing muscles of the gut
2. Reduces inflammation by protecting the lining of the gut
3. Restores the microbiome by promoting the growth of good bacteria
4. Repairs and regenerates the lining of the gut wall to protect against future flare ups

Current pharmaceutical treatments have high failure rates and severe side-effects, leading to over 50% of IBS<sup>3</sup> and IBD<sup>4</sup> patients trying complementary and alternative medicines (CAMs) in the hope of effectively managing their chronic bowel condition. As many patients and healthcare providers believe the risk benefit of CAMs to be favourable, patients are willing to invest in their health, with this market segment being significant. In 2018, expenditure on gastrointestinal supplements and OTC digestive remedies in the US alone was US\$8 billion<sup>5,6</sup>.

CEO Steve Lydeamore commented, "Anataara is highly encouraged by the successful in vitro and in vivo preclinical data reported for its GaRP OTC medicine to date and is pleased to be planning commencement of a clinical trial in irritable bowel syndrome (IBS) in the 4th quarter of calendar 2020. As anticipated in our Covid-19 market update, Anataara is proceeding with a decentralised trial design allowing participants to be recruited and participate remotely. Anataara is evaluating partnering opportunities with multinational consumer health companies."



- <sup>1</sup> Clinical Gastroenterology and Hepatology 2012: 10, 712-721.
- <sup>2</sup> Crohn's and Colitis Australia.
- <sup>3</sup> Grundmann O & Yoon S (2014) World J. Gastroenterol 20 (2). p.346.
- <sup>4</sup> Lovell R & Ford A (2012) Clin. Gastroenterol. Hepatol. 10. p.712
- <sup>5</sup> Mintel's 2018 Digestive Health U.S., July 2019.
- <sup>6</sup> 2018 category insight Report: follow your gut-a global look at Digestive Health Products.

## For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anantara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anantara.com	Sue MacLeman Chair, Anantara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anantara.com

## About Anantara Lifesciences Ltd

Anantara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anantara is a life sciences company with expertise in developing products for animal and human health. Anantara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

### Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

### Anantara Lifesciences Limited

#### Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

#### Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email [info@anantara.com](mailto:info@anantara.com) | Website [anataralifesciences.com](http://anataralifesciences.com)

